Massive trial aims to find optimal Pre-Surgery combo for esophageal cancer

NCT ID NCT04821843

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This large phase 3 study is testing different combinations of chemotherapy, radiation, immunotherapy, and targeted drugs given before surgery for esophageal cancer. The goal is to find which approach works best to improve survival. The trial will enroll 2,000 adults with stage I to IVa esophageal or esophagogastric junction cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Platinum-based chemotherapy, paclitaxel-based chemotherapy, 5-FU analog chemotherapy, immunotherapy (anti-PD-1/PD-L1 antibody), nimotuzumab, radiotherapy, and surgery
What this could lead to: If successful, this could identify the most effective combination of treatments before surgery to improve survival and reduce cancer recurrence for esophageal cancer patients.
What could go wrong: This is an early-phase study with many different treatment combinations, so results may not show a clear winner. Side effects from chemotherapy, radiation, and immunotherapy can be severe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMORADIATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced toxicity esophageal cancer Esophageal Neoplasms gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMORADIATION CHEMOTHERAPY EFFECT ESOPHAGEAL CANCER ESOPHAGOGASTRIC JUCTION CANCER IMMUNOTHERAPY SURGERY TARGETED THERAPY

Contacts and locations

Locations

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
RECRUITING

Beijing, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.